A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-c...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Mani, Aruna, Roda, Julie, Young, Donn, Caligiuri, Michael A., Fleming, Gini F., Kaufman, Peter, Brufsky, Adam, Ottman, Susan, Carson, William E., Shapiro, Charles L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2997435/
https://ncbi.nlm.nih.gov/pubmed/19051009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-008-0251-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky